Evidence map›Paper›PMID 38164339›Full record

ArticleBulletin of the World Health Organization2024

Reassessing potential economic value and health impact of effective

William P Hausdorff, John D Anderson, A Louis Bourgeois, Allison Clifford, Jessica A Fleming, Farzana Muhib, Clint Pecenka, Chloe Puett, Mark S Riddle, Suzanne Scheele and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bulletin of the World Health Organization, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. IgG Serum Antibodies toVaccines · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

William P HausdorffCenter for Vaccine Innovation and Access, PATH, 455 Massachusetts Avenue NW, Washington, D.C.20001, United States of America (USA).
John D AndersonWest Virginia University, Morgantown, West Virginia, USA.
A Louis BourgeoisCenter for Vaccine Innovation and Access, PATH, 455 Massachusetts Avenue NW, Washington, D.C.20001, United States of America (USA).
Allison CliffordCenter for Vaccine Innovation and Access, PATH, 455 Massachusetts Avenue NW, Washington, D.C.20001, United States of America (USA).
Jessica A FlemingPATH, Seattle, Washington, USA.
Farzana MuhibCenter for Vaccine Innovation and Access, PATH, 455 Massachusetts Avenue NW, Washington, D.C.20001, United States of America (USA).
Clint PecenkaPATH, Seattle, Washington, USA.
Chloe PuettStony Brook University, Stony Brook, New York, USA.
Mark S RiddleUniversity of Nevada, Reno, Nevada, USA.
Suzanne ScheeleCenter for Vaccine Innovation and Access, PATH, 455 Massachusetts Avenue NW, Washington, D.C.20001, United States of America (USA).
Karoun H BagamianBagamian Scientific Consulting LLC, Gainesville, Florida, USA.

Funding

Wellcome Trust
6 · The paper itself

Abstract

The gram-negative bacterium

Indexed as

ShigellaShigella VaccinesVaccinesChildDiarrheaGlobal HealthHumansShigella VaccinesVaccines

Identifiers

PMID38164339
PMCPMC10753284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.